Navigation Links
CD97 gene expression and function correlate with WT1 protein expression and glioma invasiveness

Charlottesville, VA (February 7, 2012). Researchers at Virginia Commonwealth University Medical Center's VCU Massey Cancer Center and Harold F. Young Neurosurgical Center (Richmond, VA) and Old Dominion University (Norfolk, VA) have discovered that suppression of Wilms tumor 1 protein (WT1) results in downregulation of CD97 gene expression in three glioblastoma cell lines and reduces the characteristic invasiveness exhibited by glial tumor cells. This finding is announced in the article, "Novel report of expression and function of CD97 in malignant gliomas: correlation with Wilms tumor 1 expression and glioma cell invasiveness," by Archana Chidambaram, Ph.D., and colleagues, published online ahead of print today in the Journal of Neurosurgery. Although further studies must be performed, the authors propose that CD97 may prove to be a new target for anti-glioma therapies.

According to William C. Broaddus, M.D., Ph.D., neurosurgeon and leader of the research team, "the invasive behavior of glioma cells is a key feature of their malignancy in the first place, and more recently there is evidence that treatment of gliomas with anti-angiogenic approaches such as bevacizumab (Avastin) may stimulate the invasive behavior of some gliomas. This may even serve as the mechanism by which these tumors fail to respond to bevacizumab treatment. That means that treatments to attack the invasiveness of gliomas by attacking CD97 expression may have special promise as a new treatment strategy."

WT1 is a transcription factor involved in the normal development of several tissue types. Usually expression of this protein is switched off when tissue reaches the normal adult stage. However, WT1 expression has been identified in numerous malignant diseasesleukemia, lung and breast cancers, sarcomas, reproductive organ tumors, and gliomas to name a few. In fact, the same team of researchers previously documented WT1 expression in 80% of glioma cells and tumor specimens. Because WT1 expression in tumor cells has been shown to play a role in resistance to radiation and chemotherapy as well as promotion of cell proliferation, invasion, and/or angiogenesis, Dr. Broaddus brought together the team to investigate what genes present in malignant gliomas could be mediated by WT1 to confer the virulence displayed by this particular tumor. According to the authors, "given its structural identityand functional history, it seemed logical that WT1 might regulate the transcription (or posttranscriptional expression) of other genes."

To this end, the research team set out to silence WT1 gene expression in malignant glioma cells and observe the effects of this silencing on other genes in these cells. The researchers did this by using short interfering RNA (siRNA) directed against WT1 in three glioblastoma cell lines: U251-MG, U1242-MG, and GBM-6.

Application of siRNA consistently suppressed WT1 gene expression levels, which in turn produced a significant reduction in cellular invasiveness. A microarray analysis identified other genes that were affected by WT1 silencing. These included 27 genes that were significantly downregulated and 11 that were significantly upregulated. The authors point out that nine of the 27 downregulated genes have putative or established roles in oncogenesis, and seven of the 11 upregulated genes have putative or established roles in tumor suppression. All but one gene demonstrating dysregulation during WT1 silencing have at least one potential binding site for WT1 in their promoter regions; the other gene (PDGF-D) has binding sites for Egr1, which recognizes and binds consensus binding sequences shared by WT1.

Prior to this study, there were no reports of CD97 overexpression in glioma cells. It was therefore surprising to the research team that the CD97 gene consistently displayed a direct correlation with WT1 in all three glioblastoma cell lines. Given CD97's putative role in aiding cell invasiveness and neoangiogenesis in other non-brain tumors, the decision was made to examine this cell-surface receptor specifically.

CD97 belongs to the adhesion G-proteincoupled receptor family. Western blot analysis demonstrated overexpression of CD97 protein in the three cell lines. Quantitative reverse transcriptasepolymerase chain reaction showed a six- to 21-fold increase in CD97 expression in the tumor cells over that found in normal human astrocytes, which displayed minimal CD97 expression. After siRNA transfection methods were applied to silence the CD97 gene, CD97 mRNA levels lowered significantly: approximately 50% in U251-MG cells, nearly 80% in GBM-6 cells, and 20% in U1242-MG cells. To examine whether these results would impact the glioblastoma cells' invasive capabilities, the researchers plated cells on Matrigel-coated filters of Transwell plates to see whether the cells would invade the Matrigel. In each cell type the cellular invasiveness potential decreased: to 54% of control (tumor cells) in U251-MG cells, approximately 50% of control in GBM-6 cells, and 26% of control in U1242-MG cells.

Perhaps the greatest challenge faced in treating malignant gliomas is their strong invasive capacity. The authors believe their data indicate that upregulation of CD97 mediated by WT1 possibly promotes this invasiveness. The findings of this study show a definite relationship between CD97 overexpression and the invasive quality of malignant glioma cells, which is correlated to the relationship between WT1 expression and the invasive characteristic of glioma cellsrelationships that in the future may be exploited in a therapeutic setting.


Contact: Gillian Shasby
Journal of Neurosurgery Publishing Group

Related medicine news :

1. Group settings can diminish expressions of intelligence, especially among women
2. Regulatory enzyme overexpression may protect against neurodegeneration in Huntingtons disease
3. Gene expression in mouse neural retina sequenced
4. Controlling gene expression to halt cancer growth
5. Novel technique reveals both gene number and protein expression simultaneously
6. High EGFR expression a predictor for improved survival with cetuximab plus chemotherapy
7. Gene expression changes in nasal cells may help identify lung cancer in earliest stages
8. Smokers undergo the same changes in gene expression as patients with COPD
9. Gene expression predicts chemotherapy sensitivity of triple-negative breast cancer
10. RxPONDER trial will evaluate whether gene expression test can drive chemotherapy choice
11. Low doses of penta-brominated diphenyl ether flame retardants alter gene expression
Post Your Comments:
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from reveals that ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... , , , WHEN: , , ... , , , LOCATION: , , , Online, with free registration ... PANELISTS:  , , , Frost & Sullivan,s Global Vice President of ... Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager , ... witnessing an exceptional era. Several new demand spaces, such as innovative ...
(Date:6/23/2016)... announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered in Bogota. Colombia ... ... ... ... Astellas is a pharmaceutical ...
Breaking Medicine Technology: